New Zealand Coastal Seafoods (ASX:NZS) (‘NZCS’) is a leading added-value producer of seafood products, premium marine ingredients, and nutraceutical products. The Company has traditionally focussed on the sale of Ling Maw; however, with the acquisition of Kiwi Dreams International in March 2020, NZCS expanded into the global nutraceuticals market with a one-year strategic supply agreement for Europe, as the Company continues discussions with customers worldwide.
NZCS’s nutraceutical products include Green Lipped Mussel Powder, Oyster Powder and Astaxanthin extract products, with the Company building a business case for extracting oils from marine ingredients. NZCS is nearing the launch of its flagship marine collagen product, produced using proprietary intellectual property techniques in processing and extraction. The raw product is sourced from Marine Stewardship Council (MSC) certified fisheries.
By continuing the research and development of nutraceutical products, NZCS aims to expand its product offering and further position itself as a leader in the global nutraceutical market.
In 2020, the Company received European Union Listing Approval for exporting nutraceutical marine products to Europe and US Food and Drug Administration Listing Approval was received to enable the export of products to the United States. These approvals strongly position NZCS for further international growth.
To drive the next growth phase, the Company recently bolstered its Board of Directors by appointing industry leaders from the seafood and nutraceutical sectors. NZCS continues to assess potential acquisition opportunities that align with the Company’s strategy and complement and accelerate product offerings and revenue growth.
Collapsible content
ASX Annoucements
- NZCS Achieves Significant Acceleration in Sales | 06/12/2022
- Final Director's Interest Notice | 28/11/2022
- Results of Annual General Meeting and Retirement of Director | 28/11/2022
- Memorandum of Understanding secured to broaden product suite | 03/11/2022
- Quarterly Activities/Appendix 4C Cash Flow Report | 31/10/2022
- Notice of Annual General Meeting/Proxy Form | 31/10/2022
- Investor Presentation | 24/10/2022
- MoU with Leading Healthcare Distributor | 12/10/2022
- Proposed issue of securities - NZS | 05/10/2022
- Transformational and Earnings Accretive Acquisition | 05/10/202
- Appendix 4G & Corporate Governance Statement | 30/09/2022
- Annual Report to shareholders | 30/09/2022
- Notification regarding unquoted securities - NZS | 09/09/2022
- Notification of cessation of securities - NZS | 09/09/2022
- Appendix 4E and Preliminary Final Report | 31/08/2022
- Application for quotation of securities - NZS | 18/08/2022
- Proposed issue of securities - NZS | 29/07/2022
- Quarterly Activities/Appendix 4C Cash Flow Report | 29/07/2022
- Change of Director's Interest Notice | 26/07/2022
- Notification of cessation of securities - NZS | 26/07/2022
- Distribution Schedule | 21/07/2022
- Top Holders Report | 21/07/2022
- Change of Director's Interest Notice x2 | 20/07/2022
- Application for quotation of securities - NZS | 20/07/2022